The global activated partial thromboplastin test market was valued at around US$ 437.15 Million at the end of 2021. The market is projected to register a 6.3% CAGR and top a valuation of US$ 856.05 Million by 2032.
The key factors propelling the growth of the global market for activated partial thromboplastin tests are the rising demand for efficient healthcare diagnosis and treatment as well as the expansion of the healthcare sectors, including cost-effectiveness of the test and excess to these tests.
The Activated Partial Thromboplastin Test, which mostly evolved from the initial form of the test in which just the test's phospholipid content was changed, is used to measure the coagulation cascade, or blood clotting. The term "kaolin cephalic clotting" is another name for the activated partial thromboplastin test.
A certain sequence of steps is known as the route, from which blood clots. Prekallikerin, fibrinogen, factors XII, XI, IX, VIIII, V, and others are clotting factors that are employed. Phospholipids trigger the activation of factors XII and XI. Bleeding problems and monitoring patients' responses to heparin therapy and other anti-clotting medications are influencing the growth of the market for activated partial thromboplastin tests. As a result, this Activated Partial Thromboplastin Test aids in measuring the intrinsic route, which comprises a number of coagulation factors (proteins) that can be used to react to heparin.
The growth of the Activated Partial Thromboplastin Test in the near future is being driven by its usefulness for monitoring heparin therapy, screening for specific coagulation factor deficiencies, detection of coagulation inhibitors like lupus anticoagulator, specific factor inhibitor, and nonspecific factor inhibitor, among other things.
| Attributes | Details |
| Activated Partial Thromboplastin Test Market Value in 2021 | US$ 437.15 Million |
| Activated Partial Thromboplastin Test Market Value in 2032 | US$ 856.05 Million |
| Activated Partial Thromboplastin Test Market CAGR (2022 to 2032) | 6.3% |
One of the main factors propelling the expansion of the activated partial thromboplastin test market is the increasing usage of point-of-care diagnostics in healthcare, as well as improvements in healthcare infrastructure such as test accessibility, cost, and usability.
The introduction of novel coagulation tools and competitive strategic business acquisition are driving the growth of the activated partial thromboplastin test. Additionally, there are other variables such as the rise in the prevalence of blood disorders, the rise in cardiovascular diseases, the growth of the geriatric population, the rise in point-of-care, and others that are fuelling the need for the activated partial thromboplastin test.
The activated partial thromboplastin test market is expanding as a result of research and development activities as well as technological advancements, including the faster and friendlier use of devices with advanced sensor technology, designing of products used for conducting tests, the number of times it can be used, and others.
Additionally, the increased usage of disposable testing products, accessibility to online stores, the devices' easy data storage capabilities, and other factors are emerging as potential growth areas for activated partial thromboplastin.
The activated partial thromboplastin test market is broadly divided into seven major regions, North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
North America dominated the regional activated partial thromboplastin test market due to enhanced clinical diagnostic techniques, beneficial WHO initiatives, an increase in R&D activity, and others.
Europe is the second-largest contributor to the rise of the activated partial thromboplastin test market due to its high healthcare awareness, rising per capita income spending, and others.
Moreover, Asia Pacific is the region with the fastest expanding activated partial thromboplastin test market due to factors such as an increase in the elderly population, government initiatives, the importance of point-of-care testing.
Horiba International, Bio-Rad Laboratories, Takara Bio, Thermo Fisher, Johnson & Johnson, Siemens Medical Solutions, Abbott Laboratories, BioMeriux, Inc., Eiken Chemical, Life Technologies, Beckman Coulter, Inc., Danaher Corporation, Ortho-Clinical Diagnostics Corporation, Becton, Dickinson and Company, and Roche Diagnostics
| Report Attributes | Details |
| Growth Rate | CAGR of 6.3% 2022 to 2032 |
| Base Year for Estimation | 2021 |
| Historical Data | 2012 to 2021 |
| Forecast Period | 2022 to 2032 |
| Qualitative Units | Revenue in USD Million, Volume in Units, and CAGR from 2022 to 2032 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends and Pricing Analysis |
| Segment Covered |
|
| Region Covered |
|
| Key Countries Profiled |
|
| Key Players |
|
| Customization | Available Upon Request |
The global activated partial thromboplastin test market is anticipated to register a CAGR of 6.3% during the forecast period.
Horiba International, Bio-Rad Laboratories, Takara Bio, Thermo Fisher, Johnson & Johnson, Siemens Medical Solutions, Abbott Laboratories, BioMeriux, Inc., Eiken Chemical, Life Technologies, Beckman Coulter, Inc., Danaher Corporation, Ortho-Clinical Diagnostics Corporation, Becton, Dickinson and Company, and Roche Diagnostics, among others are some prominent activated partial thromboplastin test market players.
Explore Similar Insights
Activated Partial Thromboplastin Test Market
Thank you!
You will receive an email from our Business Development Manager. Please be sure to check your SPAM/JUNK folder too.
